| Status: Recommended | ||
Dabigatran etexilate (Pradaxa®) hard capsules are recommended as an option for use within NHS Wales, for the treatment of venous thromboembolic events (VTE) and prevention of recurrent VTE in paediatric patients from 8 years to less than 18 years of age. |
||
|
||
Medicine details |
||
| Medicine name | dabigatran etexilate (Pradaxa®) | |
| Formulation | 75 mg, 110 mg, 150 mg hard capsules | |
| Reference number | 2293 | |
| Indication | Treatment of venous thromboembolic events (VTE) and prevention of recurrent VTE in paediatric patients from 8 years to less than 18 years of age |
|
| Company | Boehringer Ingelheim Ltd | |
| BNF chapter | Cardiovascular system | |
| Submission type | Licence extension for paediatric use | |
| Status | Recommended | |
| Advice number | 1821 | |
| AWMSG meeting date | 08/12/2021 | |
| Date of issue | 10/12/2021 | |
| NICE guidance | ||